QuitPak

**QuitPak** is an investigational extended-release oral fixed-dose combination of **bupropion hydrochloride** and **mecamylamine hydrochloride** developed for tobacco use disorder and smoking cessation. Bupropion inhibits norepinephrine and dopamine reuptake and antagonizes neuronal nicotinic acetylcholine receptors, while mecamylamine is a noncompetitive, nonselective neuronal nicotinic acetylcholine receptor antagonist intended to reduce nicotine reinforcement and withdrawal-related craving. Cary Pharmaceuticals developed the product with IntelGenx, which developed the extended-release tablet formulation; public reports document a Phase 1 pharmacokinetic pilot study and later sources identify the program as having reached Phase 2 development. ([biospace.com](https://www.biospace.com/intelgenx-technologies-corp-and-cary-pharmaceuticals-announce-enrollment-of-phase-i-pilot-study-for-quitpak-r-int003-05))

Brand names

QuitPak

Other names

bupropion + mecamylaminebupropion/mecamylamine